DDO-6691 is a heat shock protein 90 (HSP90) inhibitor. DDO-6691 has antiproliferative effects on a variety of tumor cells, with HCT-116 colon cancer cells being the most sensitive (IC50: 1.08 μM). DDO-6691 exhibits potent tumor growth inhibition in the HCT-116 xenograft mouse model.

DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6.

DDL-357 is a potent secreted clusterin enhancer. DDL-357 reduces phospho-tau in brain and improves memory in the murine 3xTg-AD model.

DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.

DCG04 isomer-1 is an isomer of DCG04.

DC20 is an orally active non-nucleoside reverse transcriptase inhibitor with an EC50 of 0.004 μM aganist HIV-1IIIB.

DBL-6-13 is an inhibitor for WDR5 with a moderate binding affinity of 6.8 μM (microscale thermophoresis assay) and 9.1 μM (fluorescence polarization assay).

DBCO-PEG3-NHS is a biochemical assay reagent, that can be used to chemically modify proteins and antibodies with an alkynyl (DBCO) or N-hydroxysuccinimide (NHS) ester group. DBCO-PEG3-NHS can be used as a linker in PROTAC synthesis or for drug delivery and the development of biosensors and diagnostic reagents.

DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

Darlifarnib (Compound (S)-058) is the inhibitor for farnesyl transferase and geranylgeranyltransferase with IC50 ≤ 10 nM and ＞ 1000 nM. Darlifarnib exhibits good metabolic stability in human and mouse liver microsomes with the half-life time ＞ 100 min.

Danifexor is the agonist for farnesoid X receptor.

DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study.

Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model.

Cy3-PEG-FA (MW 2000) is a fluorescent folate-PEG derivative with excitation/emission wavelengths of ~550 nm/~570 nm. Cy3-PEG-FA (MW 2000) can be readily traced by its intense red fluorescent signal. Cy3-PEG-FA (MW 2000) can be used for cell imaging, folate receptor targeting and detection.

CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.

CTT2274 is a prodrug of MMAE analog. SPA107 inhibits the polymerization of tubulin, exhibits antimitotic activity (IC50 of 0.5 nM) and cytotoxicity in p53 mutated MCF-7 cell with IC50 of 0.5 nM.

CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research.

CPW-86-363 is a novel broad-spectrum cephalosporin with antibacterial activity.

CP-865569 is a CCR1 antagonist. CP-865569 can be used in the research of inflammatory diseases and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

CP-506 (compound 26) mesylate is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity.

CP-31398 can stabilize the active conformation of p53 and promote p53 activity in cancer cells with either mutant or wild-type p53. In addition, CP-31398 can upregulate p53 target genes, such as p21WAF1/Cip1 and KILLER/DR5. CP-31398 exerts an inhibitory effect on tumor growth.

Corynecin III is a Chloramphenicol-like antibiotic, which is found in Corynebacterium. Corynecin III inhibits the growth of Gram-positive and Gram-negative bacteria with MIC values of 2.6-83 μg/mL.

Corynecin I is an antibiotic produced by Corynebacterium hydrocarboclastus, and its precursor (D-(-) threo-p-amino phenyl serinol-N-acetylamine) has a minimal inhibitory effect on the synthesis of Corynecin from mevalonic acid.

Conteltinib tetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride salt form of Conteltinib. Conteltinib tetrahydrochloride is the inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. Conteltinib tetrahydrochloride exhibits a synergistic anti-tumor efficacy with Cabozantinib.

C-MS023 is a photo-activatable MS023 based cereblon ligand and a linker used in PROTAC technology. Thalidomide-piperidine-C2-piperazine-Boc can be used for synthesis of PROTACs.

CM-728 is a oxazepine-naphthoquinone that has cytotoxic and bactericidal effect. CM-728 is a human peroxiredoxin-1 inhibitor. CM-728 is an oxidative stressor that affects mitochondrial function.

CM112 is a selective protein arginine methyltransferase 1 (PRMT1) degrader by tethering hydrophobic tag, adamantane, to MS023 with a 5-PEG linker. CM112 induces the degradation of PRMT1 in various solid cancer cell lines. CM112 can also target the nonenzymatic function of PRMT1 by downregulating the stability of the orphan receptor TR3. CM112 is promising for research of cancers.

CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models.

Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects.

CL2A-FL118 is a drug-linker for synthesis of ADC molecule Sac-CL2A-FL118.